CALIX (CALX) CEO Exercises Options and Sells 176K Shares Under 10b5-1
Rhea-AI Filing Summary
CALIX, INC. Form 4 summary Michael Weening, President & CEO and a director, reported multiple option exercises and share sales on September 10-11, 2025. He exercised stock options with a $7.84 strike to acquire 176,000 shares in aggregate and reported underlying option holdings totaling 300,000, 292,010, and 274,000 shares after each exercise line. Concurrently he sold 176,000 shares at prices of $62 and $63 per share. The filing states 100% of the exercised options were vested and exercisable as of November 27, 2023, and the sales were effected under a Rule 10b5-1 trading plan adopted February 28, 2025. The report was signed by an attorney-in-fact on behalf of Mr. Weening on September 11, 2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider exercised vested options and sold shares under a 10b5-1 plan, a routine liquidity event with no new compensation disclosed.
The transactions reflect option exercises at a $7.84 strike and near-immediate sales at $62-$63, generating cash proceeds while retaining a meaningful residual ownership stake per the reported option balances. The use of a Rule 10b5-1 plan clarifies timing and provides affirmative defense against insider trading claims. From a market-impact perspective, these are sizeable share sales by the CEO but are pre-planned and disclosed promptly.
TL;DR: Transactions appear procedurally compliant: vested option exercise, sales under an established 10b5-1 plan, and prompt Form 4 disclosure.
The filing explicitly notes full vesting as of November 27, 2023, and adoption of a 10b5-1 trading plan on February 28, 2025, which supports procedural governance standards for insider transactions. The signature by an attorney-in-fact is disclosed. No other governance actions or departures are indicated in the form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 18,010 | $0.00 | $0.00 |
| Exercise | Common Stock | 18,010 | $7.84 | $141K |
| Sale | Common Stock | 18,010 | $63.00 | $1.13M |
| Exercise | Stock Option (right to buy) | 150,000 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 7,990 | $0.00 | $0.00 |
| Exercise | Common Stock | 150,000 | $7.84 | $1.18M |
| Sale | Common Stock | 150,000 | $62.00 | $9.30M |
| Exercise | Common Stock | 7,990 | $7.84 | $63K |
| Sale | Common Stock | 7,990 | $63.00 | $503K |
Footnotes (1)
- F1. 100% of the shares subject to the option were fully vested and exercisable on November 27, 2023.
FAQ
What transactions did CALX insider Michael Weening report on Form 4?
Were the exercised options vested for Michael Weening (CALX)?
Were the sales by the CALX CEO part of a 10b5-1 trading plan?
Who signed the Form 4 for Michael Weening (CALX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.